Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD | Market Cap | 119.63M +63.8% |
| Revenue (ttm) | 6.64M +78.2% |
| Net Income | -14.59M |
| EPS | -0.00 |
| Shares Out | 10.88B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,343,332 |
| Average Volume | 6,000,024 |
| Open | 0.0100 |
| Previous Close | 0.0100 |
| Day's Range | 0.0100 - 0.0110 |
| 52-Week Range | 0.0070 - 0.0170 |
| Beta | n/a |
| RSI | 59.91 |
| Earnings Date | May 11, 2026 |
About Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limit... [Read more]
Financial Performance
In fiscal year 2025, Alterity Therapeutics's revenue was 5.44 million, an increase of 35.32% compared to the previous year's 4.02 million. Losses were -12.15 million, -36.48% less than in 2024.
Financial StatementsNews
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing d...
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for E...
Alterity Therapeutics Transcript: KOL event
ATH434 demonstrated up to 48% slowing of MSA progression in phase II with a strong safety profile, supported by robust biomarker and imaging data. The upcoming phase III trial will use a 50 mg dose, rigorous patient selection, and validated endpoints, with regulatory alignment and key catalysts expected in 2026.
Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development
Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 progra...
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
Alterity Therapeutics (ATHE) announced it has received regulatory feedback following a Type C meeting with the FDA regarding its planned Phase 3 development program for ATH434 in Multiple System Atrop...
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA
Alterity Therapeutics (ATHE) Shows Promising Results in Phase 2 Trial for MSA
Alterity Therapeutics presents new data analyses from ATH434 trial
Alterity Therapeutics (ATHE) announced the presentation of new data analyses from the Phase 2 trial of ATH434, demonstrating clinical efficacy in patients with Multiple System Atrophy. The analysis wa...
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previou...
Alterity Therapeutics appoints Cunningham to Board of Directors
Alterity Therapeutics (ATHE) announced the appointment of Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Cunningham’s appointment further...
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback
Alterity Therapeutics (ATHE) Prepares for Phase 3 Trial After FDA Feedback
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
Alterity Therapeutics (ATHE) announced it has received regulatory feedback following a Type C Meeting with the FDA regarding its planned Phase 3 development program for ATH434 in Multiple System Atrop...
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its p...
Alterity Therapeutics Transcript: NWR Virtual Healthcare Conference
ATH434 demonstrated robust efficacy in phase II for MSA, showing significant slowing of disease progression and strong safety. Commercial potential is high, with peak sales estimated at $2.4 billion and broad neurologist support. Phase III is planned globally, with key milestones expected this year.
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics appoints Daniel Claasen as chief medical advisor
Alterity Therapeutics (ATHE) announced that Daniel Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also
Alterity Therapeutics recognizes MSA Awareness Month
Alterity Therapeutics (ATHE) recognizes Multiple System Atrophy, MSA, Awareness Month this March and the importance of raising awareness for a rare neurological disorder with no approved treatment opt...
Alterity Therapeutics recognizes MSA Awareness Month
Alterity Therapeutics (ATHE) recognizes Multiple System Atrophy, MSA, Awareness Month this March and the importance of raising awareness for a rare neurological disorder with no approved treatment opt...
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies –
Alterity Therapeutics provides corporate update
Alterity Therapeutics (ATHE) released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2025. Key highlights: Phase 2 data for ATH434
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and mult...
Alterity Therapeutics highlights key 2026 objectives
Alterity Therapeutics (ATHE) issued a letter to shareholders, which read in part, “Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434,